Following the premise that good news needs to be shared, Pharm Exec is proud to announce that one of our sister Advanstar publications, Medical Economics, has been selected as Media Brand of the Year by Medical Marketing and Media (MM&M) magazine.
Following the premise that good news needs to be shared, Pharm Exec is proud to announce that one of our sister Advanstar publications, Medical Economics, has been selected as Media Brand of the Year by Medical Marketing and Media (MM&M) magazine. The fact that MM&M is one of Pharm Exec’s lead competitors in the life sciences editorial space should not impair its non-partisan good judgment-after all, it could be said that the stressed ranks of the B-to-B segment is trending toward one big publication anyway.
Medical Economics is a venerable play, with a publication record that dates back to 1923. Like many titles with a long track record, the magazine hit some bumps several years ago, but new leadership and a commitment to making one with the customer-175,000 reading primary care physicians-has put the grease back on the wheels. Ad revenues rose nearly 40 percent from 2010 to 2011, while the readership average per issue posted a 3.9 percent increase over roughly the same period, much higher than the average 1 percent score in this market segment. It’s a performance that lends credence to the principle that money follows quality.
How did this happen? The turnaround built heavily on a deep-dive effort to engage with the readership and understand what the magazine could do for it. Says Advanstar’s executive vice president Georgiann Decenzo, “We refocused on specific ways to deliver value to our audience of primary care physicians, a community challenged left and right by external forces that threaten its very existence. Information, analytics, and advice on coping with these challenges was defined as our editorial mission-every feature is bench-marked around a precise mission: to help these physicians stay in practice.”
With the magazine performing nicely in terms of ad revenue, the next step is a redesign and overhaul of Medical Economics’ online offerings, including a new website due for unveiling later in the spring.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.